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Abstract
Background: Pregnant women with hepatitis B virus (HBV) infection can transmit the infection to their infants,
screening of patients and appropriate interventions reduce vertical transmission. This audit was conducted to assess
adherence to the national guidelines for management of HBV infection in pregnancy.
Methods: A retrospective audit was conducted on pregnant women diagnosed with hepatitis B on screening in
antenatal clinics, across four hospitals in London over 2 years (2009–2010). Data was collected from antenatal
records and discharge summaries using a standard audit form. The outcomes measured included HBV serological
markers, HBV DNA, detection of other blood borne viruses and referral to hepatology services, administration of
active and passive prophylaxis to infants at birth. Descriptive statistics are presented. Proportions were compared
using the χ2 test and 95% confidence intervals (CI) were calculated for prevalence estimates. Analyses were
conducted using STATA 12.
Results: HBsAg was detected in 1.05% (n = 401, 95% CI 0.95-1.16) of women attending an antenatal appointment,
12% (n = 48) of the women were at a high risk of vertical transmission (HBe Ag positive or antiHBe and HBeAg
negative or HBV DNA >106 IU/ml). Only 62% (n = 248) women were referred to hepatology or specialist clinics and
29% (n = 13) of women of high infectivity were on antiviral agents. Testing for hepatitis C and delta virus was
suboptimal. 75% (n = 36) of the infants at a high risk of acquisition of HBV received both active and passive
prophylaxis.
Conclusion: In certain sectors of London, implementation of the pathway for management of women with
hepatitis B and their infants is suboptimal. National guidelines should be followed and improved intersectorial
sharing of information is needed to reduce the risk of women of high infectivity being lost to follow up.
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Background
Chronic hepatitis B virus (HBV) infection remains
endemic in many parts of the world and there are over
2 billion infected individuals worldwide [1]. The risk of
chronicity of hepatitis B is inversely related to the age of
acquisition of infection; vertical transmission is associated
with a risk of chronicity of more than 80% [2]. Infants with
chronic infection have a 25% lifelong risk of developing
cirrhosis and/or hepatocellular carcinoma [3]. Screening
of pregnant women for HBV and managing infected
women and their infants appropriately in order to
interrupt mother-to-child transmission is therefore of
paramount importance.
The risk of vertical transmission of HBV is 70–90%
when the woman is hepatitis B e antigen (HBeAg) positive,
and around 40% when HBeAg is absent [4-7]. Active or
passive immunisation or both reduces the risk of vertical
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transmission by 90% [8]. A high maternal viral load (VL)
increases risk of transmission to the child [9], with babies
born to women who are HBeAg positive and have a high
VL (above 2 × 107 IU/ml or log8 copies/ml) having an
estimated transmission risk of at least 10% despite use of
hepatitis B immunoglobulin (HBIG) and vaccination [10].
Use of antivirals in pregnancy is suggested as a means to
reduce this risk [10-12]. However safety and efficacy data
on use of antivirals for transmission purposes are not
robust.
The UK Department of Health first published guidelines
for antenatal screening for hepatitis B, vaccination and
HBIG prophylaxis for infants at high risk of transmission,
contact tracing and referral pathways in 1998 [8]. These
best practice guidelines were updated in April 2003 [13]
and more recently in 2011 [14-16]. The NHS Infectious
Diseases in Pregnancy Screening (IDPS) Programme in
England is responsible for ensuring that all pregnant
women are routinely offered screening for hepatitis B,
together with HIV, syphilis and susceptibility to rubella as
part of their antenatal care. Routine antenatal screening
for hepatitis B for all pregnant women became national
policy in April 2000. All women confirmed as hepatitis B
surface antigen (HBsAg) positive, and those with a prior
diagnosis, should have infectivity markers, i.e. HBeAg and
antibody (anti-HBe) determined and be promptly referred
to an appropriate specialist service. HBV vaccination is
recommended for all exposed babies, with those born to
mothers at high risk of transmission offered HBIG as well
as vaccination [13]. In late 2008, HBV DNA was included
in the risk assessment of transmission determining
the need for HBIG administration at birth [14] and
in September 2010, the IDPS Programme published
updated standards for hepatitis B screening, including
referral pathways to hepatology/specialists, and screening
of family [15]. Overall there is high coverage of antenatal
screening for hepatitis B in the UK; in London, 98% of
pregnant women were screened in 2006, with approxi-
mately 1200 infants born to mothers with HBV infection
annually [17]. In England, in 2011 0.42% of pregnant
women screened for HBV were HBsAg positive overall,
with the highest prevalence in London at 1.02%, this
represented a slight decline in overall prevalence over
the past five years, from 0.47% in 2007 [18].
Despite existence of national guidelines, we observed
that practices varied with regards to clinical management
of pregnant women with hepatitis B, and their infants, and
therefore performed an audit with maternity, hepatology,
virology and paediatric colleagues in North Central
London to assess adherence to UK guidelines for man-
agement of pregnant women with hepatitis B and their
infants neonates [13,14] in 2009 and 2010. A secondary
objective was to estimate the prevalence of HBsAg
seropositivity in pregnant women in this setting, and to
describe the characteristics of women with chronic
hepatitis B.
Methods
An audit was carried out across four teaching and district
general hospitals in London providing antenatal services
to the local population of approximately seven boroughs
of London following the observation of variable practices
in clinical management of hepatitis B in pregnancy. The
audit population was pregnant women booking for
antenatal care from 1st January 2009 to 31st December
2010 with hepatitis B, i.e. those testing positive for
HBsAg at booking or with a prior diagnosis. For the
HBsAg prevalence estimates, data on all pregnant
women booking during this time period were used.
Data were collected using an audit data form, and
were retrospectively extracted from antenatal booking
records, pharmacy records and maternal and neonatal
discharge summaries. The audit was registered in all four
centres and was compliant with local clinical governance
policies. The management of HBsAg seropositive women
and their neonates was audited against the national guid-
ance/standards applicable in 2009 and 2010 (Table 1).
Data on demographics (age at booking, ethnicity), HBV
serological markers (Hepatitis B e antigen [HBeAg] and
antibody to e antigen [anti HBe]), HBV DNA testing, con-
firmatory serology, other tests (delta virus, HCV, HIV),
maternal antiviral therapy, maternal referral and neonatal
immunisation (HBIG and/or vaccine) were collected.
Definitions
HBV DNA (viral load -VL) was quantified as log IU/ml,
and categorized as >107, 106 to 107, 102 to 105 IU/ml
and undetectable.
Statistical analysis
The data from the four centres were assimilated in a
common database and analysed. For prevalence esti-
mates, 95% confidence intervals (CI) were calculated.
Descriptive statistics are presented. Proportions were
compared using the χ2 test and 95% confidence intervals
(CI) were calculated for prevalence estimates. Analyses
were conducted using STATA 12 (Stata Corp, College
Station, Texas, USA).
Results
Prevalence of HBsAg seropositivity and characteristics of
pregnant women with HBV
A total of 38,227 pregnant women were booked for ante-
natal care during 2009 and 2010, of whom 401 were
HBsAg positive (1.05%; 95% CI 0.95, 1.16) overall. There
was no difference in prevalence between 2009 (194/18473,
1.05%) and 2010 (207/19755, 1.05%) (p = 0.5). Hospital 4
(H4) had significantly higher prevalence than the other
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three hospitals (p < 0.001), with prevalence of ≥2% in both
2009 and 2010 (Figure 1). There were no cases of acute
hepatitis B noted during the study period.
Table 2 shows the socio-demographic characteristics
of the pregnant women with hepatitis B by hospital:
overall, 39% of women were black African (n = 158), 21%
Asian (mainly Chinese) (n = 84), 19% white (n = 78), 17%
(n = 67) other or mixed ethnicity, with 4% (n = 14) hav-
ing no information available. Median age at antenatal
booking was 29 years (range of 15 to 46 years). With re-
spect to serological markers of infectivity, 9% (34/401) of
women were HBeAg positive and anti HBe negative,
90% (359/401) were HBeAg negative, anti HBe positive
and eight women were HBeAg negative and anti HBe
negative. The proportion of women with high infectivity
markers was similar across the study hospitals (Table 2).
Sixty- six percent of the women across the 4 hospitals
had their serology reconfirmed (263/401) (Table 2).
Management of pregnant women with HBV infection
In all four hospitals, referrals to hepatology services were
made via Maternity by the Specialist Midwife. Sixty-two
percent (248/401) of the women were referred to hepatol-
ogy for further management of hepatitis B in pregnancy;
68% (48/70), 49% (44/89, of whom 20 women transferred
care elsewhere and 1 miscarried), 86% (55/64) and 51%
(101/200) were referred in H1, H2, H3 and H4
respectively.
Overall, HBV DNA quantitation was carried out for
293 (73%) women: 76% (26/34) of those HBeAg positive
and anti HBe negative, 73% (261/359) of those HBeAg
negative and anti HBe positive and 75% (6/8) of those
HBeAg negative and anti HBe negative. Patterns of VL
stratified according to markers of infectivity are presented
in Figure 2. Of the 293 women with VL quantitation, 18
(6%) had HBV DNA levels above 107 IU/ml, 8 (3%) had
levels at 106–107, 143 (49%) had levels of 102–105 and the
remaining 124 (42%) had undetectable levels (Additional
file 1: Table S1).
There was very high coverage of HIV testing, with
99% (399/401) women receiving an HIV antibody test.
Approximately half (53%, 212/401) of the women received
serological testing for hepatitis C and 31% (124/401) for
delta virus. There was a wide variation in coverage of test-
ing for delta virus between hospitals, ranging from 98%
(H3) to 0% (H2), with coverage of 6% and 32% in H1 and
H4 respectively. One woman (1/124, 0.8%) was positive
anti-HDV and HDV RNA. Two hospitals tested around
one-third of pregnant women with HBV infection for
hepatitis C antibodies (H1 30% and H4 34%), compared
with in excess of 80% in the other hospitals (H2 82% and
H3 89%).
Antiviral treatment for pregnant women with hepatitis
B was being offered in two of the study hospitals in 2009
and 2010. Of the 18 women with VL > 107 IU/ml and
thus eligible for antiviral therapy (Table 1), one had a
miscarriage, 13 were under care at hospitals not providing
antivirals and four were treated with antivirals (lamivudine
or tenofovir) depending on local protocol. A further 9
women thought to be at high risk of transmitting hepatitis
B to their infants (i.e. HBeAg positive, VL between 106 to
107 IU/ml, antiHBe and HBeAg negative) were also on
antivirals.
Management of infants
Of the 401 women, 6 miscarried and 69 transferred care
to another hospital, giving 326 infants delivered in the
audit hospitals, of whom all received the first dose of
hepatitis B vaccine immediately after birth, with an
intention to complete an accelerated course according to
the Department of Health, UK guidelines (Table 3) [13].
There was no vaccination data available for the remaining
Table 1 Audit standards used
2003 Standards to support the UK antenatal screening
programme [13]
• Antenatal screening for Hepatitis B should be offered to all women
at booking
• Infectivity markers HBeAg and anti HBe determined for all samples
confirmed as HBsAg positive; other
• Markers at discretion of physician
• Initial clinical assessment of women identified as HBsAg positive is
carried out at the earliest opportunity
• By those with expertise in managing hepatitis B/hepatology
• Referral of partner and family for screening
• First dose of vaccine given at or shortly after birth.
• Immunisation of infant as follows:
Vaccine HBIG
HBsAg positive & HBeAg positive Yes Yes
HBsAg positive without e markers Yes Yes
Acute hepatitis B during pregnancy Yes Yes
HBsAg positive and anti-HBe positive Yes No
2008 update to immunisation green book [14]: Immunisation of
infant as above plus:
HBsAg positive, HBeAg negative, anti-HBe negative Yes Yes
HBsAg positive & known to have HBV DNA Yes Yes
>1 x 106 IUs/ml in an antenatal sample*
2008 British viral hepatitis group guidelines [22]
• All newly diagnosed women should undergo
appropriate testing, assessment and referral as for
non-pregnant individuals (including HBV DNA, Delta
virus, HCV, HIV
• Women with HBV DNA >107 IU/ml should be considered for therapy
with a potent antiviral agent from 32 weeks of pregnancy
*Where DNA measurement has been performed to inform maternal
management. HBV (hepatitis B virus), HBsAg (hepatitis B surface antigen),
HBeAg (hepatitis B e antigen), anti HBe (hepatitis B e antibody), HBIG
(Hepatitis B immunoglobulin).
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69 births to women who delivered elsewhere or were lost
to follow up.
The first dose of hepatitis B vaccine was administered
by the maternity team, with a view of referring the baby
to the general practitioner, community services or pae-
diatricians to complete the remaining doses and check
the anti HBs levels at the end of the primary course.
Table 3 shows the number of infants of high-risk
mothers who received HBIG in addition to vaccination.
48 infants were eligible for HBIG according to the
national guidelines [13,14]; 36 infants received HBIG.
Ten women with a high risk of transmission to the baby
moved care or delivered elsewhere and a further two
had a miscarriage. In addition to the 36 babies, it was
found that 6 more babies from 2 hospitals received
HBIG without an appropriate indication; this was attrib-
uted to different policies or guidelines being followed by
hepatologists and paediatricians instead of following the
national guidelines.
Discussion
This multicentre retrospective audit, conducted in North
Central London, was based on data of women who booked
in the antenatal services at the four participating centres.
The audit assessed adherence to the UK Department of
Health guidelines, UK published in 2003 [13] for man-
agement of pregnant women with hepatitis B applicable
at the time (i.e. 2009–2010). There is high coverage of
antenatal screening for hepatitis B in the UK; in London,
98% of pregnant women were screened in 2006, with
Figure 1 Prevalence of Hepatitis B (HBsAg positive) among women booking for antenatal care, by hospital of booking (H1,H2,H3,H4),
2009–2010.
Table 2 Socio-demographic and serological markers of infectivity in pregnant women with hepatitis B, stratified by
hospital (n = 401)
Hospital 1 (H1) Hospital 2 (H2) Hospital 3 (H3) Hospital 4 (H4)
Median (range) or N (%)
HBsAg positive N = 70 N = 89 N = 64 N = 178
Age (years) 32 (18–44) 28 (17–45) 30 (20–43) 26 (15–46)
Ethnicity
Black African 20 (29) 45 (51) 19 (30) 74 (42)
Asian 27 (39) 20 (22) 15 (23) 22 (12)
White 8 (11) 11 (12) 19 (30) 40 (22)
Other/mixed 12 (17) 7 (8) 9 (14) 39 (22)
Not stated 3 (4) 6 (7) 2 (3) 3 (2)
HBV serology
HBeAg positive and anti HBe negative 8 (11) 7 (8) 5 (8) 14 (8)
HBeAg negative and anti HBe positive 60 (86) 82 (92) 58 (91) 159 (89)
HBeAg negative and anti HBe negative 2 (3) 0 1 (2) 5 (3)
Confirmatory HBV serology 59 (84) 72 (81) 27 (42) 105 (59)
HBV (hepatitis B virus), HBsAg (hepatitis B surface antigen), HBeAg (hepatitis B e antigen), anti HBe (hepatitis B e antibody).
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approximately 1200 infants born to mothers with HBV
infection annually [17].
The prevalence of hepatitis B in pregnant women in
our audit was found to be 1.05% of the total antenatal
bookings. In England, in 2011 0.42% of pregnant women
screened for HBV were HBsAg positive overall, with the
highest prevalence in London at 1.02%; this represented
a slight decline in overall prevalence over the past five
years, from 0.47% in 2007 [18]. In a surveillance study of
antenatal women in London, the overall prevalence of
hepatitis B in 2007 was 1.17%, ranging from 0.26% to
2.39% across the NHS Trusts [19]. We demonstrated a
wide variation in prevalence between hospitals, from
0.4% to 2.3%, which may have reflected differences in
the local populations, particularly ethnicity. However
our sector is a relatively high prevalence area.
Sixty percent of the pregnant women with hepatitis B
were Black African or Asian, which is consistent with a
recent study in Birmingham in which 33%, 24% and 11%
of antenatal HBV cases in 2004–2008 were in Black
African, Pakistani and Chinese women respectively;
the highest prevalence of hepatitis B was in pregnant
women of Black African (3.93%), White non-British
(2.05%) and Pakistani (0.82%) origin [20]. However this
was in contrast to a large cross sectional UK study which
showed a predominance of South and South East Asian
ethnicity amongst patients with hepatitis B [21].
The vast majority (data not shown) of infected women
in the audit were newly diagnosed in pregnancy and not
already under the care of hepatology services, thus
representing an excellent opportunity for case detection
and extended family testing. We found that referral of
pregnant women with HBV to hepatology services was
suboptimal, at only 62%. The NHS IDPS Programme
standards for hepatitis B were updated in September
2010; these changes acknowledged the organisational
challenges of screening and of appropriate maternal and
infant management, which involves a range of teams and
included key performance indicators, such as maternal
referrals to be made to an appropriate specialist service
for clinical assessment within 6 weeks of a confirmed
positive HBsAg test [15]. The finding that two-fifths of
Figure 2 Patterns of hepatitis B viral load and serological markers among women in whom HBV DNA quantitation was undertaken in
pregnancy (n = 261) in the 4 study hospitals over 2009–2010.
Table 3 Management of infants born to women with hepatitis B
1st dose of hepatitis B vaccination Hospital 1
n/70 (%)
Hospital 2
n/89 (%)
Hospital 3
n/64 (%)
Hospital 4
n/178 (%)
Total
n/401 (%)
Vaccinated 58 (83) 68 (76) 57 (89) 143 (80) 326 (81.3)
Miscarriages/deaths 1 (2) 1 (1) 1 (2) 3 6 (1.5)
No data 11 (15) 20 (22) 6 (11) 32 (18) 69 (17.2)
Total 70 (100) 89 (100) 64 (100) 178 (100) 401 (100)
Hepatitis B immunoglobulin (HBIG) administration Number of neonates given Hepatitis B immunoglobulin (HBIG) in addition
to Hepatitis B vaccine
Hospital 1 (%) Hospital 2 (%) Hospital 3 (%) Hospital 4 (%) Total (%)
HBIG given appropriately/number of high risk infants delivered in
audit hospitals eligible for HBIG
11/11 (100) 2/7 (29) 5/8 (63) 18/22 (82) 36/48* (75)
HBIG given without indication 4 0 2 No data 6
*From Hospitals 2, 3 and 4: 2 women had a miscarriage and 10 moved care elsewhere.
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infected women were not referred to specialist care un-
derscores the need for this indicator. Standardisation of
a patient referral pathway (Additional file 2: Figure S1)
across the sector and strategies such as appointing a spe-
cialist midwife focusing on blood borne viruses/infections
in pregnancy will facilitate referrals and help to achieve
these targets. Future national audits will be able to
investigate the impact that the updated standards have
had on maternal management.
Although serological HBV markers were performed on
all women diagnosed with HBV infection, HBV DNA
quantitation was performed less frequently.
HBV DNA is a significant determinant of vertical
transmission and the importance of viral load quantita-
tion is illustrated by the case of the 3 women who would
have been classified as “low risk” in the absence of HBV
DNA levels. For the 27% of women in whom HBV DNA
quantitation was not performed, risk of transmission
could not be fully evaluated. National guidelines for HBV
immunisation recommended that infants should receive
HBIG where maternal HBV DNA exceeds 1 × 106 IU/ml;
the guidance states that viral load should not be quantified
with the specific purpose of determining need for passive
immunisation, but can be used for this purpose if mea-
sured for maternal health (Table 1). BVHG guidelines
have recommended viral load measurement as standard
in all people newly diagnosed with hepatitis B since
2008 [22]. With regard to the use of antivirals for trans-
mission purposes, our findings reflect the audit period
and the fact that the national guidance in 2003 did not
encompass indications for antivirals or specialist referral
pathways [13], although BVHG guidelines recommended
that antivirals should be considered for women with high
viral loads [22]. Only two of the four hospitals included in
the audit provided antiviral therapy for preventing vertical
transmission, with 4 women identified to be at high risk
of transmission (HBV DNA >107 IU/ml) commencing
treatment, consistent with BVHG guidance [22].
Although not part of the screening programme, testing
of patients with HBV infection for other blood borne
viruses is good medical practice and should be routinely
performed, as recommended by BVHG and international
guidelines [22-24]. There was good coverage with ante-
natal HIV testing, as would be expected for a test offered
routinely, and on an opt-out basis in the UK, but screen-
ing for hepatitis C and delta virus was carried out in
substantially fewer women with HBV, with considerable
variation between hospitals. Testing of other blood
borne viruses should also be standardised and laboratory
systems could aid in ensuring this is performed.
Overall, one in six women transferred care or were lost
to follow-up prior to delivery, of which of particular con-
cern was the proportion of women with a high risk of
transmission (16%, 10/63). This highlights the importance
of adopting policies and pathways focusing on this group
of women and their infants, who represent a highly mobile
population. All infants delivered in the audit hospitals
were known to have received the first dose of hepatitis B
vaccine. There was similarly good coverage with HBIG:
of the mothers identified to be of high infectivity, 2
miscarried and 10 delivered elsewhere, with the infants
of the remainder all receiving HBIG. In addition, we noted
that a small number of infants (6) received HBIG despite
not strictly meeting the high risk criteria. This was ex-
plained by conflicting guidelines being followed by paedia-
tricians and hepatologists where maternal VL > 103 IU/ml
was used as a cut-off for administration of HBIG.
There were several limitations to this audit. There is lack
of data about the exact gestational age of the women at
the time of diagnosis of hepatitis B and absence of data on
the number with hepatitis C or HIV co-infection. Data
were not available for women who presented and were di-
agnosed with HBV infection in labour, and we were unable
to assess the management of neonates delivered in other
hospitals. Lack of complete data included in discharge
summaries of women and neonates not only hampered
the audit, but present considerable challenges (including
further vaccination and contact tracing of families) to
those responsible for the on-going care and management
of the mother and infant, such as general practitioners,
primary health care services, paediatricians and hepatolo-
gists. Audit of completion of the infant vaccination sched-
ule was beyond the scope of this work. All the hospitals
involved in the audit have since introduced new services
and methods of working to improve the outcomes for
women with hepatitis B and their infants (example of the
improved patient referral pathway used by one hospital is
shown in Additional file 2: Figure S1). These changes will
be subject to a prospective audit to demonstrate their
effectiveness.
Conclusion
Standardisation of the pathway of management of women
with hepatitis B and their infants based on national guide-
lines is required to improve the care provided across the
sector, and rigorous auditing should be implemented. The
new detection of maternal infection should be seized as an
opportunity to provide appropriate care to the mother and
family contacts as well as the child. Testing for other
blood borne viruses should be included in the pathway.
Data regarding the use of antivirals in pregnancy should
be systematically collected as their use in pregnancy for
reducing risk of transmission is relatively new and ques-
tions remain regarding efficacy and safety. As the man-
agement of these women and infants is complex, there
is a need for the different teams within hospitals and
the community to work much more closely together
and improved intersectorial sharing of information is
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needed to reduce the risk of women of high infectivity
being lost to follow up.
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